SABCS 2023 | NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancer

Gabriel N. Hortobagyi, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses data reported from the Phase III NATALEE (NCT03701334) trial evaluating ribociclib plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer. The final protocol-specified analysis of the primary endpoint of invasive disease–free survival (iDFS) showed significant iDFS with ribociclib plus NSAI over NSAI alone. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.